Abstracts

2001

Selected Abstracts from the American Society of Hematology, December 2001, Orlando, Florida

• Involvement of the Lympho-Myeloid Stem Cells in Different Cytogenetic Subgroups of Myelodysplastic Syndromes
  
• The Evolving Ethical Dilemma of Low Dose Melphalan Chemotherapy in Advanced MDS/AML: Quality of Life in Remission Versus Predictable Induction of 17P Deletion
  
• Resolving Complex Aberrant Karyotypes in MDS and AML Evolving From MDS With 24-Color-FISH: A Study of 40 Cases
  
• Do Patients With Low-Grade Myelodysplastic Syndrome Mobilise Normal Hemopoietic Progenitors?
  
• In Vitro Amplification and Differentiation of Myelodysplastic Syndromes Deriving Erythroid Progenitors
  
• Pediatric MDS in Brazil: The Brazilian Working Group on MDS in Childhood, First Results and its Educational Impact
  
• MDR1 Gene Expression in Poor-Risk Acute Myeloid Leukemia (AML) With Partial or Complete Monosomy 7
  
• A Phase II Study of Anti-Lymphocyte Versus Anti-Thymocyte Globulin as Immunomodulating Therapy in Low-Risk Myelodysplastic Syndromes
  
• Pathophysiologic Role of Tumor Necrosis Factor-a in Myelodysplastic Syndrome (MDS)- Effects of Anti-TNF Therapy With Soluble TNF Receptor-FC Fusion Protein (Enbrel)
  
• Secondary Myelodysplastic Syndromes Following Treatment With Azathioprine

Selected Abstracts from the Sixth International Symposium. (Spring 2001)

• Meeting Report: Fifth International Symposium on Myelodysplastic Syndromes

2000

Selected Abstracts from the American Society of Hematology, December 2000, San Francisco, California

• Biologic Determinants of Clinical Response to Thalidomide in Myelodysplasia
  
• Thalidomide as a Single Agent or in Combination with Topotecan, Pentoxifylline and/or Enbrel in Myelodysplastic Syndromes (MDS)
  
• Danazol for the Treatment of Thrombocytopenia in Myelodysplastic Syndrome
  
• Low Dose Interleukin-11 is Well-Tolerated and Induces Platelet Responses in Myelodysplasia and Other Bone Marrow Failure States
  
• High Dose (HD) Chemotherapy in High Risk (HR) Myelodysplastic Syndrome (MDS): Covariate Adjusted Comparison of Five Regimens
  
• Comparison of Interphase Fish and Metaphase Cytogenetics to Study Myelodysplasia: An Eastern Cooperative Oncology Group (ECOG) Study
  
• Clonal Cytogenetic Anomalies Suggestive of A Myelodysplastic Syndrome in Patients With Morphologically Normal Bone Marrow Aspirates
  
• Addition of Thalidomide (T) to Chemotherapy Did Not Increase Remission Rate in Poor Prognosis AML/MDS
  
• HLA DR15 (DR2) is Over-Represented in Myelodysplastic Syndrome (MDS) and is Associated With a Response to Immunosuppression
  
• Validation of the WHO Proposals for a New Classification of Myelodysplastic Syndromes: Analysis of 1640 Patients
  
• Myelodysplastic Syndromes, from FAB to WHO: Comparison of Classifications on 431 Unselected Patients from a Single Institution

Selected Abstracts in MDS
Adapted from abstracts presented at the American Society of Hematology 1999. (Spring 2000)

• Meeting Report: Fifth International Symposium on Myelodysplastic Syndromes
  
• Phase II Study of Amifostine in Patients With Myelodysplastic Syndromes (MDS)
  
• Encouraging Response To Amifostine, Pentoxifylline, Ciprofloxacin, Dexamethasone (A-PCD)±Topotecan in Patients with Myelodysplastic Syndromes (MDS)
  
• Dna Demethylating Therapy in MDS: The Experience With 5 Aza-2'-Deoxycytidine (Decitabine)
  
• Antithymocyte Globulin for the Treatment of Patients With 'Low Risk' Myelodysplastic Syndromes
  
• Low-Dose Melphalan Induces Favourable Responses in Elderly Patients With High-Risk MDS or Secondary AML
  
• A New Combination Chemotherapy Using Topotecan, Fludarabine, Ara-c and G-CSF for Aggressive Myelodysplastic Syndromes and Acute Myelogenous Leukemia in the Elderly: Dose Finding for Topotecan Study
  
• Combination Chemotherapy with Risk Factors-Adjusted Dose Attenuation for High-Risk Myelodysplastic Syndromes and Their Leukemia in the Japan Adult Leukemia Study Group
  
• Depletion of Lymphocytes Increases the In Vitro Hemopoiesis In Long-Term Bone Marrow Cultures (Ltbmc) from Patients With Myelo-dysplastic Syndrome (Mds): Implications for the Immunosuppressive Therapy of Mds
  
• Evaluation of 396 Successfully Analyzed Bone Marrow Karyotypes of Children With MDS and Juvenile Myelomonocytic Leukemia (JMML) as Collected by the European Working Group of Childhood MDS
  
• Quality of Life In Individuals with Myelodysplastic Syndromes (MDS): A Descriptive Study
  
• Erythroid Apoptosis In Ringed Sideroblastic Anemia (RARS): Influence of FAS Antibodies, Caspase Inhibition and G-csf
  
• Spontaneous Growth of Cfu-gm in Myelodysplastic Syndromes (MDS): Should Chronic Myelomonocytic Leukemia (Cmml) Be Reclassified?
  
• T Helper Type 2 (Th2) Population is Increased in Peripheral Blood of Patients with Myelo-dysplastic Syndrome (Ra) and Normalized After Cyclospolin A Treatment in Accord with Hematological Improvement
  
• Heteroplasmic Mutations of Mitochondrial DNA in Acquired Idiopathic Sideroblastic Anemia and Other Myelodysplastic Syndromes
  

1998 and Beyond

• Conference on Anemia in Cancer Patients Held
  
• Prognostic Impact of Cytogenetic Investigations in 258 Patients with Primary MDS
  

Abstracts from the MDS Simultaneous Session, presented at the MDS simultaneous session of the 40th Annual Meeting of AHS and printed in Blood 1998; 92 (no. 10, suppl 1), are reprinted here with permission from the authors.

• Prolonged Transfusion Independence and Disease Stability in Patients with MDS Responding to Antithymocyte Globulin (ATG)
  
• Frequent Hypermethylation of P15/INK4B in Patients with MDS Is Decreased Following Treatment with Decitabine
  
• Intensive Chemotherapy Followed by Stem Cell Transplantation for Patients with Poor-Risk MDS and Secondary AML
  
• Telomere Stability Is Frequently Impaired in High-Risk Groups of Patients with MDS
  
• Angiogenesis in MDS: Analysis of 59 Cases
  
• Increased Cytogenetic Abnormalities in MDS and Occupational or Environmental Exposure
  
• Topotecan and High-Dose Cytarabine Is an Active Combination Regimen in MDS and Chronic Myelomonocytic Leukemia
  
• Phase II Study of Amifostine in Patients with MDS: Impact on Hematopoiesis
  
• MDS: A Stem Cell Disorder Treated by Stem Cell Transplantation
  

Abstracts from the Corporate Friday symposium "MDS: Epidemiology, Molecular Biology, Pathology, and Innovations in Treatment," held in conjunction with the 1998 American Society of Hematology meeting in Miami, Florida.

Members of the symposium faculty (from L to R): Carlo Aul, Neal Young, Judith Chessells, Martyn Smith, John Bennett, Alan List, Yataro Yoshida. Cherly Willman is not pictured.

• Innovations in Modifying the Stem Cell Environment in MDS
• Is Pancytopenia in MDS Immune Mediated?
  
• The Etiology of MDS: Speculations Based on the Effects of Benzene and Alkylating Agents
  
• Pediatric MDS: Treatment Approaches
  
• Epidemiology of Myelodysplastic Syndromes
  
• Oncogenes, Growth Factors, and Apoptosis
  
• Molecular Pathology of MDS
  
• The History of MDS: The Role of the FAB Classification and the Development of Risk Assessment
  
• Benzene Exposure and Risk of MDS/AML
  
• Increasing Incidence of MDS: Real or Fictitious?
  
• Recent Developments in the Prognostic Classification for MDS: Results of the International Risk
  
• The Influence of Cytogenetic Abnormalities on Treatment Outcome after Intensive Antileukemic Therapy for Patients with High-Risk MDS: A Joint Study of the EORTC, EBMT, SAKK, and GIMENA Leukemia Groups
  
• Telomere Dynamics in Myelodysplastic Syndromes
  
• Cytogenetic Studies in 429 Myelodysplastic Syndromes Patients: Prognostic Value
  
• Childhood Myelodysplasia: Cytogenetic and Fish Studies
  
• Molecular Mapping of the Del(5q) in Myelodysplastic Syndromes
  
• Aggressive Chemotherapy in MDS: The DYsseldorf Experience
  
• Idarubicin, Fludarabine, Cytarabine, and G-CSF (FLAG-Ida) for the Treatment of High Risk MDS or AML
  
• Intensive Chemotherapy with Quinine in Myelodysplastic Syndromes (MDS)
  
• Promotion of Multilineage Hematopoiesis in Patients with Myelodysplastic Syndrome: A Phase I/II Clinical Trial with Amifostine
  
• The Seattle Experience with Bone Marrow Transplantation (BMT) for Myelodysplasia (MDS)

Reprinted with permission from Leukemia Research 21 (April 1997), suppl. 1.

• Update on Allogeneic and Autologous Transplantation
  
• Erythropoietin in the Management of MDS-Related Anemia
  
• Yataro Yoshida Introduction
  
• Plenary Session 1: Epidemiology and Classification
  
• Plenary Session 2: Prognostic Factors
  
• Plenary Session 3: Cell Biology
  
• Plenary Session 4: Cytogenetics in MDS
  
• Plenary Session 5: Molecular Biology in MDS
  
• Plenary Session 6: Treatment I, Hematopoietic Growth Factors and Differentiating Agents
  
• Plenary Session 7: Treatment II, Chemotherapy in MDS
  
• Plenary Session 8: Treatment III, Bone Marrow Transplantation in MDS
  
• Benzene Exposure Clearly Linked with MDS
  
• Novel Anti-Cytokine Approach to Treat MDS

Home | Overview | Board of Directors | Supporters | Press Releases | Symposia | Membership | Newsletters | Articles | Abstracts | Funding | Patient Info.
Centers of Excellence | International Patient Registry | Clinician Resources | International Research Update | Contacting | Forums | Links & Archive